Siden er beregnet for helsepersonell. E2011-1681. 19.01.2012

Skriv ut siden
Champix - Referanser


1. Coe JW et al. Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474-3477.

2. Jorenby DE et al.
Effi cacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation. A randomized controlled trial. JAMA 2006; 296:56-63.

3. Gonzales D et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006; 296:47-55.

4. Nides M et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32:664-675.

5. Jarvis MJ. Why people smoke. BMJ 2004; 328:277-279.

6. West R, Shiffman S. Fast Facts. Smoking cessation. Indispensable guides to clinical practice. 2004, Oxford: Health Press

7. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nature Neuroscience 2005;

8:1465-1470. 8. Hughes JR. New treatments for smoking cessation. CA Cancer J Clin 2000; 50:143-151.

9. Hughes JR et al. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99:29-38.

10. Cahill Ket al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2008, Issue Art. No.:CD006103.

11. West R et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008; 197:371-377.

12. Aubin H-J et al. Varenicline versus transdermal
nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax. 2008; 63:717-24.

13. CHAMPIX Summary of Product Characteristics.

14. Tonstad S. et al. Effect of Maintenance therapy with Varenicline on Smoking cessation. JAMA 2006; 296 (1): 64- 71.

15. IMS Midas data: July 2006 - December 2008

16. Sosial- og helsedirektoratet. Røykeavvenning i primærhelsetjenesten; retningslinjer for primærhelsetjenestens arbeid med røykeavvenning. Juni 2004.

17. AKTUELT I FORENINGEN. Tidsskr Nor Legeforen 2008; 128:2000.


Snakk med legen

Det er bevist at det å snakke med legen om røykeslutt fordobler sjansene for å lykkes med å bli røykfri (8).

LAST NED BROSJYRE | Hjelp dine pasienter til å slutte å røyke!

Referanser - klikk på bildet

Last ned brosjyre om Champix som hjelp til å overvinne nikotinavhengighet

Pfizer AS, Postboks 3, 1324 Lysaker | Tlf: 67 52 61 00 Faks: 67 52 61 99 | | Pfizer AS har ikke ansvar for innhold på eksterne nettsider som det lenkes til.
Bruksvilkår og behandling av personopplysninger | Informasjon om cookies